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with a point mutation. Two patients with point mutations eventu-
ally experienced progression of their disease. Tumor progression
was not observed in the patients with exon 19 deletions. The
mean progression free interval was 430 days (CI [294,567]) for
the whole series.
Conclusions: The observations add support to the importance of
EGFR status as predictors of response to TKIs. Exon 19 deletions
seem to predict the best responses to TKIs.
doi:10.1016/j.ejcsup.2006.04.030
S30. ANTI-TUMOR APPLICATIONS OF ACTIVATING TOLL-LIKE
RECEPTOR 9 WITH PF-3512676 (FORMERLY CPG 7909)
Arthur M. Krieg. Coley Pharmaceutical Group.
Unmethylated CpG dinucleotides are relatively common in viral
and bacterial DNA, but are rare in vertebrate DNA. Toll-like
receptor 9 (TLR9) detects these ‘‘CpG motifs’’ as a sign of infec-
tion, and can be activated for therapeutic purposes by CpG
motifs in synthetic oligodeoxynucleotides (CpG ODN), such as
PF-3512676 (formerly called CPG 7909, or CpG 2006). PF-3512676
engages TLR9 in B cells and plasmacytoid dendritic cells (pDC),
thereby stimulating innate and adaptive immunity, including
antigen-specific Th1-like T cell responses. Murine studies
showed anti-tumor activity of PF-3512676 as a monotherapy
for relatively small tumors. Tumor regression was associated
with the induction of a tumor-specific CTL response. PF-
3512676 has been administered at various dose levels to more
than 1000 humans, and has shown activity as a monotherapy
in phase I human clinical trials when administered by intratu-
moral injection in basal cell carcinoma, by subcutaneous injec-
tion in cutaneous T cell lymphoma (CTCL), melanoma, and
renal cell carcinoma, and by intravenous injection in non-Hodg-
kin’s lymphoma.
Although the demonstrated activity as a monotherapy pro-
vides some proof-of-concept for the use of PF-3512676 in cancer
therapy, we considered that combination approaches may pro-
vide greater efficacy. We theorized that disruption of the tumor
using conventional anti-tumor therapies may reduce the
tumors’ resistance to immune mediated attack induced through
TLR9 activation with PF-3512676. In murine models regression of
larger tumors could be induced when PF-3512676 was used in
combination with other therapies, including radiotherapy, surgi-
cal resection, monoclonal anti-tumor antibodies, and chemo-
therapy. The combination of PF-3512676 or other CpG ODN
with certain chemotherapy regimens, including paclitaxel or
gemcitabine, increased the generation of tumor antigen-specific
CTL and/or improved tumor regression and survival in meta-
static tumor models. These studies also demonstrated the
involvement of T cells in the synergy between CpG and paclit-
axel, consistent with the hypothesis that this combination
induces enhanced tumor specific adaptive immune responses.
These encouraging results in mouse models have been extended
into human therapy in a controlled Phase II trial, where 112
patients with locally advanced or metastatic non-small cell lung
cancer were randomized to receive either chemotherapy alone,
or in combination with PF-3512676. The combination with che-
motherapy provided a statistically significant improvement in
objective response rate, and a trend to prolonged survival (1 year
survival 33% vs. 50%, P = 0.08). The safety and tolerability of
these TLR9 agonists has generally been good, with the major
adverse events being transient injection site reactions and flu-
like symptoms. Phase III trials of PF-3512676 in combination
with 2 doublet chemotherapy regimens (paclitaxel plus carbo-
platin or gemcitabine plus cisplatin) for first-line therapy of
locally advanced or metastatic NSCLC in 1600 patients were ini-
tiated in late 2005.
doi:10.1016/j.ejcsup.2006.04.031
S31. GENE PROFILING IN MELANOMA – WHAT HAVE WE
GAINED?
Keith Hoek. Department of Dermatology, University Hospital of
Zu¨rich, Switzerland.
In the mid 1990s one of the first targets of DNA microarray analysis
was melanoma. For over a decade researchers have made increas-
ing use of this technology in their efforts to understand the molec-
ular biology underlying this disease. Most work has concentrated
on class-comparison approaches which assess the transcriptional
differences between aggressive and less aggressive variants, or
explored the consequences of activating mutations in members
of the MAPK pathway. Other studies examined the effects of vari-
ous in vitro treatments including UV, retinoids, demethylation and
hypoxia. The general outcome of these studies have been the gen-
eration of ever longer lists of genes nearly all of which are guilty
through association. But who are the master criminals in the
crowd? Where are the strings which draw these multitudinous
factors together and who are the puppetmasters behind them?
DNA microarrays may have brought us closer to the facts, but
what they all mean is not at all obvious to the majority of research-
ers. Just where in these details lies the devil of malignancy?
doi:10.1016/j.ejcsup.2006.04.032
S32. TUMOR STROMA-ASSOCIATED ANTIGENS FOR
ANTI-CANCER IMMUNOTHERAPY
Ju¨rgen C. Becker, Valeska Hofmeister, David Schrama. Julius-
Maximilians-University of Wuerzburg, Department of Dermatology,
Wuerzburg, Germany.
Immunotherapy has been widely investigated for its potential
use in cancer therapy and it becomes more and more apparent
that the selection of target antigens is essential for its efficacy.
Indeed, limited clinical efficacy is partly due to immune eva-
sion mechanisms of neoplastic cells, e.g. downregulation of
expression or presentation of the respective antigens. Conse-
quently, antigens contributing to tumor cell survival seem to
be more suitable therapeutic targets. However, even such
antigens may be subject to immune evasion due to impaired
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processing and cell surface expression. Since development and
progression of tumors is not only dependent on cancer cells
themselves but also on the active contribution of the stromal
cells, e.g. by secreting growth supporting factors, enzymes
degrading the extracellular matrix or angiogenic factors, the
tumor stroma may also serve as a target for immune interven-
tion. To this end several antigens have been identified which
are induced or upregulated on the tumor stroma. Tumor
stroma-associated antigens are characterized by an otherwise
restricted expression pattern, particularly with respect to differ-
entiated tissues, and they have been successfully targeted by
passive and active immunotherapy in preclinical models. More-
over, some of these strategies have already been translated into
clinical trials.
The work is supported by the grant KFO 124-1/2 of the Deut-
sche Forschungsgemeinschaft.
doi:10.1016/j.ejcsup.2006.04.033
S33. MOLECULAR PHENOTYPING OF MINIMAL RESIDUAL
DISEASE IN SOLID CANCER – DEFINING THE MARKERS FOR
TUMOR PROGRESSION?
Klaus Pantel. Institut fu¨r Tumorbiologie, Universita¨tsklinikum
Hamburg-Eppendorf, Germany.
Metastasis is the major cause of deaths in patients with solid
tumors. Occult micrometastatic spread of tumor cells might be
the seed for the occurrence of overt metastases in distant
organs within the years following successful surgical resection
of the primary tumor. The two major approaches to detect such
‘‘minimal residual disease’’ are immunocytochemical staining
and polymerase chain reaction analysis. These assays are sensi-
tive enough to detect a single disseminated tumor cell (DTC) in
the background of millions of normal cells [Pantel and Braken-
hoff. Nat Rev Cancer 2004;4:1–9]. For epithelial tumors, cytokera-
tins have become the best marker for the immunocytochemical
detection of DTCs in blood, lymph nodes and bone marrow
(BM).
Micrometastatic cells in BM can be easily collected from the
iliac crest, and BM seems to be a common homing organ for DTCs
derived from various types of malignant epithelial tumors (e.g.,
breast, lung, prostate or colorectal cancer). DTCs are present in
BM samples of 20–40% of patients even in the absence of lymph
node metastases (stage N0) or clinical signs of overt distant
metastases (stage M0). A pooled analysis on 4703 breast cancer
patients [Braun et al., NEJM 2005;353:793–802] has shown that
the detection of DTC in BM is a marker for an increased risk to
develop metastatic relapse. The molecular and biochemical char-
acterization of DTCs helps to identify progression markers
towards overt metastases and new therapeutic targets for thera-
pies that are specifically directed against minimal residual dis-
ease. This information may refine the current DTC detection
approaches, which the major goal of the EU-funded consortium
‘‘DISMAL’’ coordinated by K.P.
doi:10.1016/j.ejcsup.2006.04.034
S34. TARGETING Plk1 FOR CANCER THERAPY
Mathias Schmidt, Hans-Peter Hofmann, Karl Sanders, Volker
Gekeler, Thomas Beckers. Altana Pharma AG, Therapeutic Area
Oncology, Byk-Gulden Str. 1, D-78467 Konstanz, Germany.
A stringent control of mitosis is mandatory to warrant the
accurate segregation of sister chromatids in dividing cells.
Eukaryotic cells have evolved sophisticated mechanisms to
monitor faithful progression through each phase of mitosis in
order to prevent the occurrence of aneuploid daughter cells.
Polo like kinase 1 (Plk1) has been identified to be a key player
for G2-M transition and mitotic progression in both, normal
and tumor cells. Multiple essential roles have been assigned
to Plk1 at the entry into M-phase, mitotic spindle formation,
condensation and separation of chromosomes, exit from mito-
sis by activation of the anaphase-promoting complex and in
cytokinesis.
We have employed chimeric antisense oligonucleotides and
siRNA to investigate the molecular alterations after targeted
interference with Plk1 in a multitude of human cancer cells.
Suppression of Plk1 mRNA inevitably resulted in a dramatic
increase of the mitotic index followed by the onset of apoptosis.
Mitotically arrested cells displayed randomly separated con-
densed chromosomes and the occurrence of multiple spindle
poles with well-formed asters. Induction of apoptosis was
strictly dependent on cell cycle progression: Genetically engi-
neered RKO human colon adenocarcinoma cells with inducible
expression of the cdk inhibitor p27Kip1 were completely refrac-
tory to Plk1 depletion-induced apoptosis when they were
arrested in the G1 phase of the cell cycle. Various mitotic mark-
ers including MPM-2, cdc25c, cyclinB1, or phospho-histone H3
were investigated to explore the molecular consequences of
Plk1 depletion. While most marker proteins only showed altera-
tions typical for mitosis, modifications of cdc25c allowed distinc-
tion between mitotic targeting via Plk1 or via other mechanisms,
such as microtubule inhibitors. cdc25c was fully phosphorylated
solely in paclitaxel-treated cells, while it was only partially
phosphorylated in Plk1 depleted cells despite the fact that both
treatments caused a profound mitotic arrest. This differential
phosphorylation of cdc25c was used to test whether a pharma-
cological inhibitor of Plk1 kinase activity would exert the same
cellular effects as interference with Plk1 on an mRNA level. In
deed, pharmacological intervention with Plk1 using a specific
Plk1 kinase inhibitor induced exactly the same molecular altera-
tions and displayed the cell cycle-dependent cytotoxicity as Plk1
interference on an mRNA level. Taken together, these data sub-
stantiate the attractiveness of Plk1 as candidate for mitotic tar-
geting of cancers.
doi:10.1016/j.ejcsup.2006.04.035
S35. REGULATION OF UCN-01 INDUCED MITOTIC CELL DEATH
BY PRO- AND ANTI-APOPTOTIC PATHWAYS
Celia Vogel, Christian Hager, Holger Bastians. Philipps University
Marburg, Institute for Molecular Biology and Tumor Research (IMT),
Marburg, Germany.
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